CB2 cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: Role of CB2 receptor in pain

Neurochemistry International

Volumn 53, Issue 6-8, 2008, Pages 309-316

  Páldy, Eszter ^a   Bereczki, Erika ^a   Sántha, Miklós ^a   Wenger, Tibor ^b   Borsodi, Anna ^a   Zimmer, Andreas ^c   Benyhe, Sándor ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Opioid receptor; 35S GTP S binding; Brainstem; CB1 receptor knockout mouse; CB2 cannabinoid receptor; CB2 receptor knockout mouse; Noladin ether; Radioligand binding; Real time PCR; SR144528

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANINE NUCLEOTIDE BINDING PROTEIN; MU OPIATE RECEPTOR; NOLADIN ETHER;

ANIMAL TISSUE; ARTICLE; BRAIN STEM; CONTROLLED STUDY; FOREBRAIN; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BINDING;

ANIMALS; BINDING, COMPETITIVE; BORNANES; BRAIN STEM; DOWN-REGULATION; ENDOCANNABINOIDS; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; GLYCERIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NOCICEPTORS; PAIN; PYRAZOLES; RADIOLIGAND ASSAY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, OPIOID, MU; RNA, MESSENGER;

ANIMALIA; MUS;

EID: 56349093753     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2008.08.005     Document Type: Article

References (61)

1. Agarwal N., Pacher P., Tegeder I., Amaya F., Constantin C.E., Brenner G.J., Rubino T., Michalski Ch.W., Marsicano G., Monory K., Mackie K., Marian C., Batkai S., Parolaro D., Fischer M.J., Reeh P., Kunos G., Kress M., Lutz B., Woolf C.J., and Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. 10 (2007) 870-879
2. Ashton J.C., Friberg D., Darlington C.L., and Smith P.F. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci. Lett. 296 (2006) 113-116
3. Balazsa T., Biro J., Gullai N., Ledent K., and Sperlagh B. CB1-cannabinoid receptors are involved in the modulation of non-synaptic [3H]serotonin release from the rat hippocampus. Neurochem. Int. 52 (2008) 95-102
4. Beltramo M., Bernardini N., Bertorelli R., Campanella M., and Nicolussi E. CB2 receptor-mediated antihyperalgesia: possible direct involvements of neuronal mechanisms. Eur. J. Neurosci. 23 (2006) 1530-1538
5. Benyhe S., Farkas J., Tóth G., and Wollemann M. Met5-enkephalin-Arg6-Phe7, an endogenous neuropeptide, binds to multiple opioid and nonopioid sites in rat brain. J. Neurosci. Res. 48 (1997) 249-258
6. Bisogno T., Martire A., Petrosino S., Popoli P., and Di Marzo V. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. Neurochem. Int. 52 (2008) 307-313
7. Buckley N.E., McCoy K.L., Mezey E., Bonner T., Zimmer A., Felder Ch.C., Glass M., and Zimmer A. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. Eur. J. Pharmacol. 396 (2000) 141-149
8. Calignano A., La Rana G., Giuffrida A., and Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 394 (1998) 277-281
9. Childers S.R., Fleming L., Konkoy C., Marckel D., Pacheco M., Sexton T., and Ward S. Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann. N. Y. Acad. Sci. 654 (1992) 33-51
10. Cinar R., Freund T.F., Katona I., Mackie K., and Szucs M. Reciprocal inhibition of G-protein signaling is induced by CB1 cannabinoid and GABAB receptor interactions in rat hippocampal membranes. Neurochem. Int. 52 (2008) 1402-1409
11. Clayton N., Marshall F.H., Bountra C., and O'Shaughnessy C.T. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96 (2002) 253-260
12. da Fonseca P.D., Klein A., de Castro Perez A., da Fonseca P.C.M., de Francischi J.N., and Duarte I.D. The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. Br. J. Pharmacol. 154 (2008) 1143-1149
13. De Vry J., Jentzsch K.R., Kuhl E., and Eckel G. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav. Pharmacol. 15 (2004) 1-12
14. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., and Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 3376-3380
15. Fezza F., Bisogno T., Minassi A., Appendino G., Mechoulam R., and Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and sensitive method for its quantification in rat tissues. FEBS Lett. 513 (2002) 294-298
16. Golech S.A., McCarron R.M., Chen Y., Bembry J., Lenz F., Mechoulam R., Shohami E., and Spatz M. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res. Mol. Brain Res. 132 (2004) 87-92
17. Gong J.-P., Onaivi E.S., Ishiguro H., Liu Q.-R., Tagliaferro P.A., Brusco A., and Uhl G.R. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 1071 (2006) 10-23
18. Gonzalez S., Cebeira M., and Fernandez-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol. Biochem. Behav. 81 (2005) 300-318
19. Gray A.C., Coupar I.M., and White P.J. Comparison of opioid receptor distributions in the rat central nervous system. Life Sci. 79 (2006) 674-685
20. Griffin G., Wray E.J., Tao Q., McAllister S.D., Rorrer W.K., Aung M.M., Martin B.R., and Abood M.E. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur. J. Pharmacol. 377 (1999) 117-125
21. Hájos N., Ledent C., and Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106 (2001) 1-4
22. Hanus L.O. Discovery and isolation of anandamide and other endocannabinoids. Chem. Biodivers 4 (2007) 1828-1841
23. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., and Mechoulam R. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc . Natl. Acad . Sci. U.S.A. 98 (2001) 3662-3665
24. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11 (1991) 563-583
25. Howlett A.C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35 (1995) 607-634
26. Ibrahim M.M., Deng H., Zvonok A., Cockayne D.A., Kwan J., Mata H.P., Vanderah T.W., Lai J., Porreca F., Makriyannis A., and Malan Jr. T.P. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 10529-10533
27. Ibrahim M.M., Porreca F., Lai J., Albrechtk P.J., Rice F.L., Khodorova A., Davar G., Makriyannis A., Vanderah T.W., Mata H.P., and Malan Jr. T.P. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 3093-3098
28. Ibrahim M.M., Rude M.L., Stagg N.J., Mata H.P., Lai J., Vanderah T.W., Porreca F., Buckley N.E., Makriyannis A., and Malan Jr. T.P. CB2 cannabinoid receptor mediation of antinociception. Pain 122 (2006) 36-42
29. Ishiguro H., Iwasaki S., Teasenfitz L., Higuchi S., Horiuchi Y., Saito T., Arinami T., and Onaivi E.S. Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. Pharmacogenomics J. 7 (2007) 380-385
30. Iverson L. Cannabis and the brain. Brain 126 (2003) 1252-1270
31. 1 receptor knockout mice. Science 283 (1999) 401-404
32. Lichtman A.H., Cook S.A., and Martin B.R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 276 (1996) 858-893
33. Lynn A.B., and Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J. Pharmacol. Exp. Ther. 268 (1994) 1612-1623
34. Mackie K. Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 101-122
35. Mailleux P., and Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding autoradiography and in situ hybridization histochemistry. Neuroscience 48 (1992) 655-668
36. 2 cannabinoid receptor agonists: pain relief without psychoactive effects?. Curr. Opin. Pharmacol. 3 (2003) 62-67
37. Maldonado R., Stinus L., Gold L.H., and Koob G.F. Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J. Pharmacol. Exp. Ther. 261 (1992) 669-677
38. Mansour A., Khachaturian H., Lewis M.E., Akil H., and Watson S.J. Anatomy of CNS opioid receptors. Trends. Neurosci. 11 (1988) 308-314
39. Mansour A., Fox C.A., Akil H., and Watson S.J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18 (1995) 22-29
40. Manzanares J., Corchero J., Romero J.J., Fernandez-Ruiz J.J., Ramos J.A., and Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trend. Pharmacol. Sci. 20 (1999) 287-293
41. Matsuda L.A., Lolait S.J., Brownstein B.J., Young A.C., and Bonner T.L. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
42. Mechoulam R., Fride E., Ben-Shabat S., Meiri U., and Horowitz M. Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur. J. Pharmacol. 362 (1998) R1-R3
43. Milligan G. G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. Drug Discovery Today 11 (2006) 541-549
44. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
45. 2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 53 (2004) 208-213
46. Onaivi, E.S., Ishiguro, H., Gong, J-P., Patel, S., Meozzi, P.A., Myers, L., Perchuk, A., Mora, Z., Tagliaferro, P.A., Gardner, E., Brusco, E., Akinshola, E., Hope, B., Lujilde, J., Inada, T., Iwasaki, S., Macharia, D., Teasenfitz, L., Arinami, T., Uhl, G.R. 2008. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PloS ONE, 3, e1640.
47. Paldyova E., Bereczki E., Santha M., Wenger T., Borsodi A., and Benyhe S. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. Neurochem. Int. 52 (2008) 321-328
48. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29 (2001) e45
49. Puskas L.G., Bereczki E., Santha M., Vigh L., Csanadi G., Spener F., Ferdinandy P., Onody A., and Kitajka K. Cholesterol and cholesterol plus DHA diet-induced gene expression and fatty acid changes in mouse eye and brain. Biochimie 86 (2005) 817-824
50. Reisine T., Law S.F., Blake A., and Tallent M. Molecular mechanisms of opiate receptor coupling to G proteins and effector systems. Ann. N. Y. Acad. Sci. 780 (1996) 168-175
51. Rice A.S. Cannabinoids and pain. Curr. Opin. Investig. Drugs 2 (2001) 399-414
52. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy Ch., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Breliére J.C., and Le Fur G. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284 (1998) 644-650
53. Sagar D.R., Millns P.J., O'Shaughnessey C.T., Kendall D.A., and Chapman V. Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur. J. Neurosci. 22 (2005) 371-379
54. 2, and KATP channels. Neurochem. Int. 52 (2008) 80-88
55. 35S]thio]-triphosphate binding. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 7242-7246
56. Tappe-Theodor A., Agarwal N., Katona I., Rubino T., Martini L., Swiercz J., Mackie K., Monyer H., Parolaro D., Whistler J., Kuner T., and Kuner R. A molecular basis of analgesic tolerance to cannabinoids. J. Neurosci. 27 (2007) 4165-4177
57. 35S](thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 47 (1995) 848-854
58. 2 receptors. Science 310 (2005) 329-332
59. Walker J.M., and Hohmann A.G. Cannabinoid mechanisms of pain suppression. Handbook Exp. Pharmacol. 168 (2005) 509-554
60. Wotherspoon G., Fox A., McIntyre P., Colley S., Bevan S., and Winter J. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135 (2005) 235-245
61. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., and Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 5780-5785